NIPPON-KINZOKU
23.7.2024 10:02:34 CEST | Business Wire | Press release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announces that it has named and registered the trademark "Fine Profile" for its cold profile rolled products, which can be used for various metals from ferrous to nonferrous, by combining its proprietary cold rolling technology and specialized equipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723992481/en/
Fine Profile is a generic term for products made by continuously processing ferrous and nonferrous metals into irregularly shaped cross sections with different thicknesses in the width direction using our unique rolling technology. It contributes to customers' process reduction, environmental improvement, manufacturing cost reduction, and yield improvement as an alternative to various processes such as cutting and grinding. (Graphic: Business Wire)
Fine Profile is our original new product that contributes to customers' manufacturing cost reduction and yield improvement as an alternative to various machining processes such as cutting and grinding, and we aim to expand sales of this product in the future.
Features
-
Cost reduction of metal processing, resource saving, energy saving
Use of a deformed cross-sectional shape contributes to reduce machining processes and waste. -
Stabilization of quality
Continuous rolling from coil provides stable supply of high quality products. -
Roll forming on metal surfaces
By rolling the uneven pattern on the roll surface, it is possible to process various designs and functions such as unique designs, oil grooves, gloss prevention, identification grooves, etc. -
Various delivery forms
We can deliver products in a variety of forms, such as record rolls, oscillate rolls, fixed-length products, and secondary processing, etc. according to customer needs. -
Shorter development period
Roll design using CAE analysis contributes to reduction of customers' development cost and time.
Metal types
Nonferrous metals: oxygen-free copper, copper alloys, aluminum alloys, pure titanium, titanium alloys, pure nickel, magnesium alloys, etc.
Stainless steel: SUS304 (L), SUS316 (L), SUS430, SUS420J2, SUS440C, etc.
Carbon steel: SS400, SPCD, SPCC, SPHC, SECC, etc.
Special steel: SCM415, SUJ2, S10C, S45C, S65C, SAE1070, SK75, SK95, SKS81, 1LSSP, etc.
* Please inquire separately for specifications other than those listed above.
Application examples
Fine Profile is developed and manufactured by our rolling technologies and co-creation with our customers that require stable quality and reliability in various applications.
- Automotive applications (Automotive drive parts, Bearing components, Vane pump parts, Engine parts, etc.)
- Electrical and electronic parts applications (Connector parts, Secondary battery terminals, Heat spreaders, Bus bars, etc.)
- Building material applications (Grating components, Braille studs, Screen components, Special fasteners, etc.)
About NIPPON KINZOKU Group
Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723992481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom